The role of indomethacin and tezosentan on renal effects induced by Bothrops moojeni Lys49 myotoxin I.
Renal changes determined by Lys49 myotoxin I (BmTx I), isolated from Bothrops moojeni are well known. The scope of the present study was to investigate the possible mechanisms involved in the production of these effects by using indomethacin (10 microg/mL), a non-selective inhibitor of cyclooxygenase, and tezosentan (10 microg/mL), an endothelin antagonist. By means of the method of mesenteric vascular bed, it has been observed that B. moojeni myotoxin (5 microg/mL) affects neither basal perfusion pressure nor phenylephrine-preconstricted vessels. This fact suggests that the increase in renal perfusion pressure and in renal vascular resistance did not occur by a direct effect on renal vasculature. Isolated kidneys from Wistar rats, weighing 240-280 g, were perfused with Krebs-Henseleit solution. The infusion of BmTx-I increased perfusion pressure, renal vascular resistance, urinary flow and glomerular filtration rate. Sodium, potassium and chloride tubular transport was reduced after addition of BmTx-I. Indomethacin blocked the effects induced by BmTx-I on perfusion pressure and renal vascular resistance, however, it did not revert the effect on urinary flow and sodium, potassium and chloride tubular transport. The alterations of glomerular filtration rate were inhibited only at 90 min of perfusion. The partial blockade exerted by indomethacin treatment showed that prostaglandins could have been important mediators of BmTx-I renal effects, but the participation of other substances cannot be excluded. The blockage of all renal alterations observed after tezosentan treatment support the hypothesis that endothelin is the major substance involved in the renal pathophysiologic alterations promoted by the Lys49 PLA(2) myotoxin I, isolated from B. moojeni. In conclusion, the rather intense renal effects promoted by B. moojeni myotoxin-I were probably caused by the release of renal endothelin, interfering with the renal parameters studied.
Barbosa
P S F
PS
Department of Physiology and Pharmacology, Federal University of Ceara, Fortaleza, Ceara, Brazil.
Martins
A M C
AM
Alves
R S
RS
Amora
D N
DN
Martins
R D
RD
Toyama
Marcos H
MH
Havt
A
A
Nascimento
N R F
NR
Rocha
V L C
VL
Menezes
D B
DB
Fonteles
M C
MC
Monteiro
H S A
HS
D000818:Animals; D017837:Bothrops; D003435:Crotalid Venoms; D016232:Endothelins / Q000378:metabolism; D054501:Group II Phospholipases A2; D007213:Indomethacin / Q000494:pharmacology*; D007668:Kidney / Q000098:blood supply / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D010741:Phospholipases A / Q000633:toxicity*; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D030162:Reptilian Proteins; D013152:Splanchnic Circulation / Q000187:drug effects; D013777:Tetrazoles / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology
D003435:Crotalid Venoms; D016232:Endothelins; D011725:Pyridines; D030162:Reptilian Proteins; D013777:Tetrazoles; D014665:Vasodilator Agents; C120582:tezosentan; D010741:Phospholipases A; D054501:Group II Phospholipases A2; C076780:myotoxin I; D007213:Indomethacin